Oncocyte Corp Quarterly Debt-to-equity in % from Q3 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Oncocyte Corp quarterly Debt-to-equity history and growth rate from Q3 2016 to Q3 2024.
  • Oncocyte Corp Debt-to-equity for the quarter ending September 30, 2024 was 335 %, a 186% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 335 +218 +186% Sep 30, 2024
Q2 2024 214 +103 +92.2% Jun 30, 2024
Q1 2024 163 +51.4 +46.2% Mar 31, 2024
Q4 2023 121 -1.75 -1.43% Dec 31, 2023
Q3 2023 117 -3.93 -3.24% Sep 30, 2023
Q2 2023 111 +1.19 +1.08% Jun 30, 2023
Q1 2023 111 +10.2 +10.1% Mar 31, 2023
Q4 2022 123 +52.9 +75.8% Dec 31, 2022
Q3 2022 121 +66.1 +120% Sep 30, 2022
Q2 2022 110 +58.8 +114% Jun 30, 2022
Q1 2022 101 +58.2 +136% Mar 31, 2022
Q4 2021 69.7 +6.13 +9.64% Dec 31, 2021
Q3 2021 55 -0.64 -1.15% Sep 30, 2021
Q2 2021 51.4 +7.95 +18.3% Jun 30, 2021
Q1 2021 42.7 +12.4 +41% Mar 31, 2021
Q4 2020 63.6 +48.4 +317% Dec 31, 2020
Q3 2020 55.7 +39.2 +238% Sep 30, 2020
Q2 2020 43.4 +20.3 +87.5% Jun 30, 2020
Q1 2020 30.3 -5.98 -16.5% Mar 31, 2020
Q4 2019 15.3 -72 -82.5% Dec 31, 2019
Q3 2019 16.5 -66.7 -80.2% Sep 30, 2019
Q2 2019 23.2 -61.3 -72.6% Jun 30, 2019
Q1 2019 36.3 -56.2 -60.8% Mar 31, 2019
Q4 2018 87.2 -5.54 -5.97% Dec 31, 2018
Q3 2018 83.1 +9.84 +13.4% Sep 30, 2018
Q2 2018 84.5 +25.9 +44.1% Jun 30, 2018
Q1 2018 92.5 +41.9 +82.6% Mar 31, 2018
Q4 2017 92.8 +50.1 +117% Dec 31, 2017
Q3 2017 73.3 +37.9 +107% Sep 30, 2017
Q2 2017 58.6 Jun 30, 2017
Q1 2017 50.6 Mar 31, 2017
Q4 2016 42.7 Dec 31, 2016
Q3 2016 35.4 Sep 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.